Display options
Cite
Hamoda H. British menopause society tools for clinicians: Progestogens and endometrial protection. Post Reprod Health. 2021;20533691211058030doi: 10.1177/20533691211058030.
Hamoda, H. (2021). British menopause society tools for clinicians: Progestogens and endometrial protection. Post reproductive health, 20533691211058030. https://doi.org/10.1177/20533691211058030
Hamoda, Haitham. "British menopause society tools for clinicians: Progestogens and endometrial protection." Post reproductive health vol. (2021): 20533691211058030. doi: https://doi.org/10.1177/20533691211058030
Hamoda H. British menopause society tools for clinicians: Progestogens and endometrial protection. Post Reprod Health. 2021 Nov 27;20533691211058030. doi: 10.1177/20533691211058030. Epub 2021 Nov 27. PMID: 34841960.
Copy Download .nbib Format: NLM
Share it on

Post Reprod Health. 2021 Nov 27;20533691211058030. doi: 10.1177/20533691211058030. Epub 2021 Nov 27.

British menopause society tools for clinicians: Progestogens and endometrial protection.

Post reproductive health

Haitham Hamoda,

Affiliations

  1. King's College Hospital, London, UK.

PMID: 34841960 DOI: 10.1177/20533691211058030

Abstract

Progestogen administration is required to oppose naturally produced or administered estrogens to provide endometrial protection. Within HRT regimens, this should be delivered for at least the same duration as that produced during the luteal phase of the monthly cycle and in the recommended doses to protect against the risk of endometrial hyperplasia and endometrial cancer. This includes progestogens administered for 12-14 days a month in sequential regimens and continuous daily intake in continuous combined HRT regimens. Shorter durations and lower doses of progestogen intake are likely to be associated with an increased risk of breakthrough bleeding, endometrial hyperplasia, and endometrial cancer.

Keywords: HRT; Progestogens; endometrial hyperplasia; endometrial protection

Publication Types